Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01355289 · ClinicalTrials.gov registry record · Phase 2
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01355289 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 65 participants.
The verdict
NCT01355289, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
Interventions
- DRUG Placebo
- DRUG Avatrombopag
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG Pegylated interferon (PEG-IFN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01355289
The ClinicalTrials.gov registry entry for NCT01355289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01355289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01355289 about?
NCT01355289 is a clinical study titled "Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501". To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
What is the current status of trial NCT01355289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2011-11. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01355289?
The interventions under investigation include: Placebo (DRUG), Avatrombopag (DRUG), Ribavirin (DRUG), Telaprevir (DRUG), Pegylated interferon (PEG-IFN) (DRUG).
Who is sponsoring clinical trial NCT01355289?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.